Drugs / KITE-439
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03912831 | Apr 2019 → Feb 2022 | human papillomavirus-related squamous cell carcinoma | Gilead Sciences | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-06-04 | Kite, A Gilead Company | Results Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors kitepharma.com ↗ |
| 2018-06-04 | Gilead Sciences | Results Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors gilead.com ↗
These findings were presented today in a poster session at the 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting in Chicago (Abstract #3043). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-06-04 | Kite, A Gilead Company | Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors kitepharma.com ↗ |
| 2018-06-04 | Gilead Sciences | Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors gilead.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KITE-439 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03912831 ↗ |
| Modality | Cell therapy | “KITE-439, an investigational autologous T-cell product expressing TCR specific for HPV16 E7” PMID 42266673 ↗ May 2026 |